216669-67-9Relevant academic research and scientific papers
HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE
-
Page/Page column 114-115, (2021/11/20)
Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors
Liang, Jun,Labadie, Sharada,Zhang, Birong,Ortwine, Daniel F.,Patel, Snahel,Vinogradova, Maia,Kiefer, James R.,Mauer, Till,Gehling, Victor S.,Harmange, Jean-Christophe,Cummings, Richard,Lai, Tommy,Liao, Jiangpeng,Zheng, Xiaoping,Liu, Yichin,Gustafson, Amy,Van der Porten, Erica,Mao, Weifeng,Liederer, Bianca M.,Deshmukh, Gauri,An, Le,Ran, Yingqing,Classon, Marie,Trojer, Patrick,Dragovich, Peter S.,Murray, Lesley
supporting information, p. 2974 - 2981 (2017/05/31)
A high-throughput screening (HTS) of the Genentech/Roche library identified a novel, uncharged scaffold as a KDM5A inhibitor. Lacking insight into the binding mode, initial attempts to improve inhibitor potency failed to improve potency, and synthesis of
Structure-selectivity relationship in alkyllithium-aldehyde condensations using 3-aminopyrrolidine lithium amides as chiral auxiliaries
Corruble, Aline,Valnot, Jean-Yves,Maddaluno, Jacques,Duhamel, Pierre
, p. 8266 - 8275 (2007/10/03)
A nonracemizing route to a set of chiral 3-aminopyrrolidines, based on 4-hydroxy-(L)-proline, is described. The induction potential of the lithium amides derived from these diamines has then been investigated in the asymmetric addition of alkyllithium com
